Tenofovir Amibufenamide

艾米替诺福韦

Report date: 2022/12/07 17:52:36
NME

Base Information

Drug NameTenofovir Amibufenamide
Drug Alias Name艾美酚胺替诺福韦恒沐HS-10234
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsHepatitis B, ChronicHepatitis BHIV Infections
Global Approved IndicationsHepatitis B, Chronic
Approved Indications in ChinaHepatitis B, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsHepatitis BHIV Infections

Other Information

ATC CodeJ05AF07J05AF13
Related LinksN/A